SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech Post author:Sam Post published:November 16, 2017 Post category:BioPharma A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace You Might Also Like Hepatares Co-Founder to Helm Merck's New R&D Center in the UK January 21, 2018 Bone Biologics Announces Appointment Of To Company???s Board Of Directors August 3, 2017 Pressure BioSciences, Inc. Appoints As Vice President Of Finance And Chief Financial Officer April 16, 2017
Pressure BioSciences, Inc. Appoints As Vice President Of Finance And Chief Financial Officer April 16, 2017